

Learner Notification

MED Learning Group

Recognizing and Managing Growth Hormone Deficiency in Pediatric and Adult Patients: What Physicians and Patients Need to Know

October 17, 2023 – October 17, 2024

Online

Acknowledgement of Financial Commercial Support

Novo Nordisk

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be viewed in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses (ANCC) Credit Designation

Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

Objectives - After Attending This Program You Should Be Able To

1. Assess the diagnostic tools that can be used to facilitate a timely and accurate diagnosis of GHD in pediatric and adult patients.
2. Evaluate results from clinical trials of approved and emerging therapies for the treatment of pediatric and adult patients with GHD.
3. Summarize dosing and monitoring strategies for the long-term management of pediatric and adult patients with GHD.
4. Facilitate continuity of care for pediatric patients transitioning into adulthood.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Commercial Interest: Relationship
Craig A.	Alter	Novo Nordisk, OPKO Health, Tolmar: Consultant
Vaidehee	Deshpande	NA
Maureen	Dever	NA
Matthew	Frese	NA
Christina	Gallo	NA
Alexis	Klinger	NA
Marissa	Mays-Verman	NA
Aimee	Meissner	NA
Jo	Shultz	NA
Lauren	Welch	NA
Kevin	Yuen	Amryt Pharma, Ascendis, Corcept Therapeutics, Crinetics, Ipsen, Novo Nordisk, Recordati, Xeris Biopharma: Consultant, Corcept Therapeutics, Novo Nordisk, Recordati:

		Speakers Bureau, Novo Nordisk, Pfizer, Recordati: Non-CME/CE Services, Amryt Pharma, Ascendis, Corcept Therapeutics, Crinetics, Sparrow: Contracted Research
--	--	---

Questions? Email Certificate@AmedcoEmail.com